In May I predicted that Zomedica investors would know whether Truforma was a hit by Christmas, but that was just a guess. Shares have not traded above $1 since late April. Meanwhile, analysts have almost nothing to speculate on, which is why ZOM stock is now locked in a trading range, below $1. The more tests Truforma can do, the easier it will be for vets to justify the expense. In addition to calling on vet networks, which have been scaling up as pet owners seek higher-quality care, Zomedica is also trying to certify assays to identify more pet diseases. Qorvo had developed Bulk Acoustic Wave sensors for analyzing radio signals, selling its gear to aerospace and telecom companies. Zomedica got its technology from Qorvo (NASDAQ: QRVO), a $20 billion radio wave analysis company. 9 Oil & Gas Stocks to Buy to Play Rising Energy Prices.The results indicate Zomedica can finance marketing of Truforma, which uses acoustic waves to test blood samples for things like adrenal disease. Revenue was $14,124 and expenses were less than $4 million, but there was $276 million in the bank from stock sales.
There was little for investors to chew on. Zomedica announced first quarter results on May 12. Institutional Distribution Intelligence.Non-Traditional Exchanges & New Markets.Directors’ and Officers’ Questionnaires.
0 kommentar(er)
